Progressive myoclonus epilepsy of Unverricht-Lundborg type (EPM1) is an autosomal recessive neurodegenerative disorder caused by mutations in the cystatin B gene (CSTB) that encodes an inhibitor of several lysosomal cathepsins. An unstable expansion of a dodecamer repeat in the CSTB promoter accounts for the majority of EPM1 disease alleles worldwide. We here describe a novel PCR protocol for detection of the dodecamer repeat expansion. We describe two novel EPM1-associated mutations, c.149G4A leading to the p.G50E missense change and an intronic 18-bp deletion (c.168 þ 1_18del), which affects splicing of CSTB. The p.G50E mutation that affects the conserved QVVAG amino acid sequence critical for cathepsin binding fails to associate with lysosomes. This further supports the previously implicated physiological importance of the CSTB-lysosome association. Expression of CSTB mRNA and protein was markedly reduced in lymphoblastoid cells of the patients irrespective of the mutation type. Patients homozygous for the dodecamer expansion mutation showed 5-10% expression compared to controls. By combining database searches with RT-PCR we identified several alternatively spliced CSTB isoforms. One of these, CSTB2, was also present in mouse and was analyzed in more detail. In real-time PCR quantification, CSTB2 expression was less than 5% of total CSTB expression in all human adult and fetal tissues analyzed. In patients homozygous for the minisatellite mutation, the level of CSTB2 was reduced similarly to that of CSTB implicating regulation from the same promoter. The physiological significance of CSTB2 remains to be determined.
Introduction
Eight mutations in the cystatin B gene (CSTB, OMIM No. 601145) encoding a cysteine protease inhibitor have thus far been reported to associate with an autosomal recessive neurodegenerative disorder, progressive myoclonus epilepsy of Unverricht-Lundborg type (EPM1, OMIM No. 254800). 1 -7 The onset of EPM1 with stimulus-sensitive myoclonus and/or tonic-clonic epileptic seizures occurs at the age of 6 -15 years with progressive ataxia manifesting later. 8, 9 Most of the disease alleles harbour an unstable expansion of at least 30 copies of a normally polymorphic 12-nucleotide, dodecamer repeat located in the promoter region of the CSTB gene. 3, 5, 7, 10 Three reported EPM1 mutations affect splice sites (c.67-1G4C, c.168G4A, c.169-2A4G), two result in amino-acid changes (c.10G4C, p.G4R; c.212A4C, p.Q71P) and two predict truncated proteins either through creating a stop codon (c.202C4T) or producing a frameshift (c.218_219delTC).
Markedly reduced CSTB mRNA expression has been reported by Northern analysis in lymphoblastoid cells of EPM1 patients who are heterozygous or homozygous for the expansion mutation. 1, 3, 4, 6, 11 Consequently, decreased inhibitory activity of the CSTB protein in these cells has been demonstrated. 12 On the contrary, by RNase protection assay normal CSTB expression levels were detected in lymphoblastoid cells and fibroblasts of patients, while blood leukocytes showed reduced mRNA level, suggesting cell-specific regulation of CSTB expression. 5 Consistent with these results, the activity of the putative CSTB promoter, which contained B50 copies of dodecamer repeats, was found to be cell-specific and varied from normal to two-to fourfold reduction. 13 The repression of transcription was proposed to result from the disrupted spacing of transcription factor binding sites from the transcription initiation site. Contrary to these results, but compatible with the Northern blot data on CSTB expression, our in vitro study with a promoter construct containing 19 copies of the dodecamer repeat in transiently transfected COS-1 cells showed a reduced promoter activity of 10-fold. 11 Later, the expanded dodecamer repeats have been shown to induce stable tetraplex secondary structures, which has been suggested to result in the repression of CSTB transcription by altered chromatin structures.
14 Here, we have characterized the CSTB gene in more detail. We describe a novel direct PCR amplification protocol, which allows reliable detection of expanded CSTB alleles from genomic DNA and describe the identification and characterization of two novel EPM1-associated CSTB gene mutations. We have further quantitated the CSTB expression in human tissues and in patients' lymphoblastoid cells by real-time PCR. Moreover, we have experimentally verified alternative splicing of CSTB and describe the characterization of a ubiquitously expressed variant, CSTB2.
Materials and methods

EPM1 patient and control samples
The novel PCR-based method to amplify the dodecamer repeat expansion from genomic DNA was validated in 16 patients with homozygous mutation for the expansion, five heterozygous expansion mutation carriers and three control individuals with no expansion, as determined by Southern blot hybridizations. The method was applied in molecular diagnostics of an Italian patient with a clinical suspicion of EPM1.
Genomic DNA from a Finnish EPM1 patient previously identified to be a heterozygous carrier of the dodecamer expansion mutation, as well as from an Italian patient (see above) with no previously known CSTB mutations were scanned for novel mutations by sequencing. The identified novel mutations were screened in a panel of 73 Finnish and 93 CEPH control individuals.
Total RNA and/or protein extracted from lymphoblastoid cells of eight EPM1 patients of which two were homozygous for the minisatellite expansion and six compound heterozygous for the expansion and either the splice site c.67-1G4C (N ¼ 4), the p.G50E missense c.149G4A (N ¼ 1) or the nonsense c.202C4T (N ¼ 1) mutation were analyzed for the CSTB gene and protein expression. One expansion mutation heterozygous carrier and two non-carrier individuals were examined as controls. CSTB and CSTB2 expression was also examined from fibroblast RNA of two expansion mutation homozygous patients and two controls. For the first-strand cDNA synthesis, total RNA was isolated using the RNAqueoust -4PCR kit (Ambion, Austin, TX, USA). The c.168 þ 1_18del mutation was characterized by RT-PCR from total RNA extracted from a fresh blood using the PAXgene Blood RNA Validation kit (Qiagen, Hilden, Germany).
The study has been approved by an institutional ethical review board at the University of Helsinki.
Mutation analysis
The amplification conditions across the dodecamer repeat expansion were modified from the Expand Long Template PCR system (Roche Diagnostics, Mannheim, Germany) and performed in a total of 20 ml reaction mix using primers 2F (5 0 -CCC GGA AAG ACG ATA CCA G-3 0 ) and 1R (5 0 -GAG GAG GCA CTT TGG CTT C-3 0 ) ( Figure 1 ) with 15 ng genomic DNA, 0.5 mM dNTP, 0.5 mM of each primer, 0.12 U enzyme mix, 1 X BSA, 5% DMSO, and 1.0 M GC-melt mix (Clontech, Palo Alto, CA, USA). Following denaturation at 941C for 2 min, PCR was carried out in 40 cycles of 941C for 10 s, 571C for 45 s, and 681C for 8 min. A final elongation was at 681C for 7 min.
For mutation scanning, 2949 bp of the CSTB gene (GenBank AF208234), including the exons, the introns, and the 5 0 and 3 0 untranslated regions, was amplified in overlapping fragments (Figure 1 Characterization of the alternatively spliced forms of CSTB The alternatively spliced CSTB transcripts were verified and isolated by PCR from the Marathon Ready Human Brain cDNA (Clontech) and/or Human Multiple Tissue cDNA panels I and II (Clontech) and sequenced. Two variant transcripts were identified from EST sequences present in ASAP or AceView databases in NCBI, while two were identified by RT-PCR. The complete coding region of mouse Cstb2 was amplified from Marathon Ready Mouse Brain cDNA library (Clontech) and testis cDNA.
Quantitative real-time PCR analysis of human CSTB and CSTB2 expression The primers and probes for the real-time expression analysis of CSTB and CSTB2 were designed to overlap exonic splice junctions with Primer Express s program (version 2.0, Applied Biosystems). Specificity for the two variants was achieved with different reverse primers. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 15 and TATA-box binding protein (TBP; Assay no. 4333769F) were used as endogenous controls.
The mRNA quantifications were carried out using the ABI Prism s 7000 Sequence Detection System (Applied Biosystems). The 25-ml reaction volume contained 30 -50 ng of lymphoblastoid cell or fibroblast cDNA or 2 ng cDNA from Human adult and fetal MTCt Panels I and II (Clontech), 300 nM forward primer (except for GAPDH; 900 nM), 300 nM reverse primer, and 200 nM probe specific to each amplicon in TaqMan Universal PCR Master Mix (Applied Biosystems). All reactions were prepared in triplicate, and a minimum of three separate runs was performed for each sample. The mRNA expression levels in different human adult and fetal tissues were calculated using the comparative C T method (user bulletin 2, ABI PRISM 7000 Sequence Detection System). The proportion of CSTB2 expression was calculated from total CSTB and CSTB2 expression. In lymphoblastoid cells and fibroblasts, the expression levels were compared to the mean percentage (7SD) of the expression in controls. For mutations with more than one patient, the mean value (7SD) of the expression level of all patients studied was calculated.
Expression analysis of the mutant CSTB proteins
Lymphoblastoid cell pellets were resuspended in lysis buffer (10 mM Tris-HCl, 100 mM NaCl, 2% Triton X-100, 1% SDS, 1 mM EDTA), 25 mg of proteins were electrophoresed on 8 -16% gradient SDS-polyacrylamide gels (BioRad, Hercules, CA, USA) under denaturing conditions, and transferred onto a Hybondt-C Extra filter (Amersham Biosciences, Uppsala, Sweden). After incubation in 1% nonfat milk in TBST overnight at 41C with a 1:1000 dilution of the CSTB polyclonal antibody (Biogenesis, Kingston, NH, USA) the protein-antibody complexes were detected with horse-radish-peroxidase-conjugated goat anti-mouse IgG (Dako, Copenhagen, Denmark) using enhanced chemiluminescence (Amersham Pharmacia Biotech, Piscataway, NJ, USA).
The CSTB coding region PCR-amplified from lymphoblastoid cDNA of the missense c.149G4A mutation patient was subcloned into pcDNA3.1 ( þ ) (Invitrogen, Carlsbad, CA, USA; Life Technologies). CSTB in pcDNA3.1 ( þ ) 16 was used as a control. 1.5 mg of expression plasmids were 
Results
Identification of EPM1 mutations
We designed a novel PCR protocol (see Materials and methods) to replace the Southern blot method used widely in the detection of the dodecamer repeat expansion in the CSTB promoter (Figure 2 ). The method was validated in 21 known homozygous and heterozygous expansion mutation carriers in whom the repeat copy number ranged from approximately 55 to 85. The method was applied to molecular diagnosis of an Italian EPM1 patient (patient J) with a clinical suspicion of EPM1, who was heterozygous for the expansion (Figure 2) . We screened genomic DNA of the Italian patient and one Finnish patient previously identified by Southern blot to be a heterozygous expansion mutation carrier for CSTB mutations by PCR and sequencing (Figure 1) . A novel c.149G4A change was identified in the Finnish patient E (Figure 3a) . It results in substitution of glutamic acid for glycine at codon 50 (p.G50E) affecting the highly conserved QVVAG papain-binding region on the CSTB protein.
A second novel mutation, observed in the Italian patient J (Figure 3b) , is a deletion of the first 18 nucleotides downstream from the 5 0 splice donor site of intron 2. On cDNA level, this results in aberrant splicing of CSTB with two different transcripts (Figure 3c ). One has an in-frame deletion of exon 2 and predicts a deletion of 34 amino acids (p.delV23_K56), while the other contains an insertion of 25 nucleotides from intron 2 resulting in a frameshift and predicting a premature stop codon (p.V57EfsX28). None of the controls carried these mutations.
Characterization of alternative splice forms of CSTB ASAP and AceView databases revealed several overlapping ESTs that suggested alternative splicing of CSTB. By combining in silico analyses with direct PCR amplification from a brain cDNA library, we isolated a variant with retention of the entire intron 2. This novel variant, CSTB2, is transcribed from two exons with an ORF of 249 bp. It encodes a putative 9.0-kDa protein of 83 amino acids, including 57 identical to CSTB followed by 26 amino acids encoded by the intron 2 sequences. The mouse Cstb2 orthologue was PCR-amplified from mouse brain and testis cDNAs producing a fragment with an ORF of 192 bp. The predicted Cstb2 protein of 64 amino acids is 81% identical with human CSTB2 in the first 57 amino acid overlap. A nucleotide BLAST search using intron 2 sequences followed by PCR amplification of human tissues cDNAs with different intronic and exonic primer combinations resulted in the identification of at least three additional partial CSTB splice variants with limited expression in colon, intestine, and prostate (data now shown). We were not able to fully assemble these splice forms by PCR, since the amplification from the 5 0 end of the cDNA favoured the major isoform.
Real-time quantitative PCR of CSTB isoforms CSTB and CSTB2 mRNA expression in different human adult and fetal tissues was quantitated using real-time PCR. In peripheral tissues, the CSTB and CSTB2 mRNAs are ubiquitously expressed, most abundantly in lung and least in heart and skeletal muscle (Figure 4a, b) . The level of Figure 2 Detection of the expanded CSTB dodecamer repeat mutation by PCR. (A, B) Expansion homozygous patients previously determined by Southern analysis. Individual E is compound heterozygous for the expansion and the missense c.149G4A mutations (see Figure 3) ; Individual J is compound heterozygous for the expansion and the deletion c.168 þ 1_18del mutations (see Figure 3) . As a size marker, the 100-bp DNA ladder was used. The arrow indicates the fragment of an approximately 193-bp normal allele with three copies of the repeat in heterozygous expansion carriers. A and B patients homozygous for the expansion mutation.
Cystatin B gene expression
T Joensuu et al endogenous CSTB2 relative to CSTB was low in all tissues examined, the ratio varying from 0.4% to approximately 4% (Figure 4c ). The CSTB mRNA expression in lymphoblastoid cells of expansion mutation homozygous EPM1 patients was markedly reduced, the mean expression (7SD) being 8.871.0% (Figure 5a ) of controls. A heterozygous expansion mutation carrier had 60.6712.7% of the expression in controls. In patients compound heterozygous for the expansion and the c.67-1G4C splice site mutations, the level of CSTB mRNA was 17.973.8% compared to controls. In a patient compound heterozygous for the expansion and the c.202C4T nonsense mutations, and in a patient compound heterozygous for the expansion and the novel We were not able to quantitate reliably the amount of the CSTB2 mRNA in lymphoblastoid cells of EPM1 patients or controls due to inter-assay variation. Instead, using mRNA extracted from fibroblasts of two patients homozygous for the minisatellite expansion mutation, similar reduction in the levels of CSTB and CSTB2 compared to controls was detected (data not shown).
Expression analysis of the mutant CSTB proteins
While reduced levels of CSTB in lymphoblastoid cells of EPM1 patients either homozygous for the expansion mutation or compound heterozygous for the expansion mutation and the c.202C4T nonsense mutation have previously been described, 16 we here investigated the expression of the c.149G4A (p.G50E) and the c.67-1G4C (p.delV23_K56) mutants by Western analysis (Figure 5b ). In the patient with the p.G50E missense Figure 4 Quantification of human CSTB and CSTB2 tissue expression by real-time PCR. The expression levels of (a) CSTB and (b) CSTB2 mRNAs in various human adult (white columns) and fetal (grey columns) tissues. The expression of CSTB and CSTB2 in the kidney, given a value of 1, was used as a reference. The expression in the other tissues is shown as a fold of the reference. The n-fold value of expression is marked above to columns. The error bars indicate 7SD. (c) Proportion of CSTB2 expression from total CSTB and CSTB2 expression in various human adult (white columns) and fetal (grey columns) tissues. The percentage of CSTB2 expression is marked above the columns.
Cystatin B gene expression T Joensuu et al mutation, a slight decrease in the amount of the CSTB protein was observed compatible with the other allele harbouring the dodecamer expansion mutation. In the patient compound heterozygous for the c.67-14G splice and the expansion mutations, no detectable CSTB was present. Next, we studied the subcellular localization of the overexpressed mutant p.G50E protein in BHK-21 cells. By immunofluorescent staining, this mutant protein was localized in the nucleus and diffusely in the cytoplasm (Figure 6b) . In contrast to the wild-type CSTB (Figure 6a ), neither granular cytoplasmic staining nor colocalization with the lysosomal LAMP1 marker protein were detected.
Discussion
The visualization of the dodecamer minisatellite expansion mutation in the CSTB promoter by PCR amplification has been challenging due to a high GC content. 3, 5, 7 The expansion has been visualized with Southern hybridization, PCR amplification followed by hybridization or PCR amplification under special conditions with deaminated DNAs as templates. 10,17 -19 Using a new PCR-based protocol to detect the expansion mutation, we were able to correctly determine the genotype previously determined by Southern blotting. 7 Expansions with repeat copy numbers of up to approximately 85, that is in the size range of most of the reported pathogenic alleles, 5,18 -20 were readily amplified. Therefore, we considered this protocol to be applicable also in clinical setting and applied it correctly in molecular diagnostics of one newly identified Italian patient. While the minisatellite expansion mutation accounts for more than 90% of EPM1 alleles worldwide, rare EPM1-associated mutations are occasionally reported. 1 -4,6,21 We here report two novel mutations that affect the CSTB transcript. The mutation in the Italian patient, an 18-bp intronic deletion, was shown to affect splicing of CSTB, with two predicted abnormal protein products. However, it remains unknown whether these are translated in vivo or are degraded after transcription. The novel p.G50E mutation in the Finnish patient affects the highly conserved QVVAG-motif in the first beta-hairpin loop important for the complex formation with the target proteases, cathepsins. 22 Amino acid changes in the QVVAG pentapeptide are likely to affect the stability or life span of the inhibitory effect of the protein, and the interactions with their target proteins. 23, 24 As in Western blot analysis of lymphoblastoid cells expression from the p.G50E mutant allele is evident, the deleterious effect of this mutation is likely to be due to impaired cathepsin interaction. In line with previous results on two EPM1-associated missense mutations (p.G4R and p.Q71P) 16 , also the mutant p.G50E protein showed loss of lysosomal localization. This further supports the physiological importance of CSTB-lysosome association, but whether this occurs through cathepsin interaction or through some other mechanism remains to be studied. Using Northern analysis and RNase protection assay the results of CSTB expression in different cell types have been somewhat controversial. Both reduced and normal expression in lymphoblastoid cells has been reported. 1,3 -6,11 We here applied TaqMan quantitative real-time PCR to determine the level of CSTB expression in lymphoblastoid cells of EPM1 patients with different mutations. Our results unequivocally show that all mutations analyzed result in down-regulation of CSTB expression. In patients homozygous for the expansion mutation, the mRNA expression level was o10%, compatible with the in vitro promoter studies that have indicated significantly reduced CSTB promoter activity. 11, 13 Concordant with the gene expression results the amount of the CSTB protein was significantly reduced both in lymphoblastoid cells and fibroblasts of expansion mutation homozygous patients. The contradictory findings of either normal or only slightly reduced CSTB mRNA by RNase protection assay 5 may be due to a more complicated experimental set-up in the assay. The c.67-1G4C change located at an invariant splice junction has been shown to result in skipping of exon 2 Cystatin B gene expression T Joensuu et al thus predicting an in-frame-deleted CSTB protein. 1 As our TaqMan assay is designed to detect transcripts with both exons 2 and 3, we expected no mRNA from the c.67-1G4C allele. However, the amount of mRNA was higher than expected implicating that the splicing defect leaks. Such partial penetrance mutations have been reported 25 and the possibility has also been discussed in relation to this mutation. 1 The c.67-1G4C mutant mRNA or the encoded polypeptide seem to be unstable, as no mutant protein was detected in either Western analysis of patient cells or in cellular transfection studies even in the presence of a proteosomal inhibitor (data not shown). In the patient compound heterozygous for the expansion mutation and the p.R68X nonsense mutation, reduced amount of the CSTB mRNA was detected by real-time PCR, which indicates the instability of the mutant transcripts. This is in line with our earlier findings that the p.R68X protein is rapidly degraded in transiently expressed BHK-21 cells. 16 In the patient compound heterozygous for the expansion mutation and the novel p.G50E missense mutation, the results between mRNA and protein expression remain controversial, as significantly reduced mRNA expression was detected in repeated TaqMan assays, whereas Western analysis suggested expression from the missense mutant allele.
Up to 60% of human genes and a minimum of 41% of mouse genes are estimated to be alternatively spliced resulting in a large number of proteins with a variety of functions or tissue-specificities. 26, 27 The amount of tissuespecific splice variants has been shown to be highest in brain. 28, 29 By combining EST database searches with RT-PCR, we were able to identify at least four novel CSTB splice forms. While three of the variants showed limited tissue expression and were not expressed in the brain, one, CSTB2, is ubiquitously expressed and conserved among human and mouse. Owing to intronic sequence retention, some of the CSTB variants are truncated on their Cterminal ends and are probable targets for nonsensemediated decay. On the other hand, they might function in regulation of CSTB expression in post-transcriptional level by inhibiting the splicing of the pre-mRNA or by representing a storage form of the immature transcripts, whose introns are removed in certain cells or tissues. The CSTB2 mRNA is also raised by intronic retention and is transcribed at very low levels. Its presence as multiple ESTs from different cDNA libraries would indicate its functional relevance. Whether it is degraded, serves a regulatory function for CSTB expression or is translated into a protein that has distinct functions from that of CSTB remains to be investigated. Cystatin B gene expression T Joensuu et al
